Natco Pharma has received final approval from the U.S. Food and Drug Administration (USDA) for abbreviated new drug applications (ANDA) for two products
On anti-cancer drug Lenalidomide capsules, Natco said it had received final approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths and tentative approval of the 2.5 mg and 20 mg strengths.
Natco also said marketing partner Breckenridge Pharmaceutical Inc. had received final approval for its ANDA for Everolimus tablets, indicated in the prophylaxis of organ rejection in kidney and liver transplantation.
